The market study evaluates the Cancer Diagnostics Market by profiling it in terms of applications, technology and geography

Cancer is a complex and potentially fatal disease that is primarily caused through environmental factors resulting in gene mutations affecting critical cell-regulatory proteins. These factors may act together or in a sequence to trigger tumor formation. Rising incidences of cancer and increasing healthcare expenditure are expected to aid the global cancer diagnostics market. The global market for cancer diagnostics is expected to grow at an exponential rate pertaining to advances in technology, favorable government initiatives and funding. Moreover, the development in companion diagnostics and advent of breakthrough detection techniques such as proteomics, metabolomics, genomics and transcriptomics are further expected to boost the demand for cancer diagnostic devices. Cancer screening is critical in improving early detection and treatment of any cancer type. Awareness and screening for cancer have increased over the last couple of decades resulting in early diagnosis of cancer and subsequent reduction of mortality. However, the ultimate goal of reducing mortality in late-stage cancer has not been satisfactorily achieved.

Request Sample Copy of the Report @

The global cancer diagnostics market was valued at USD 100,994.5 million in 2013, and is expected to grow at a CAGR of 7.6% to reach an estimated value of USD 168,649.3 million by 2020. Imaging, endoscopy, biopsy and tumor biomarker tests altogether comprise the global cancer diagnostics market. Imaging for cancer detection remains the largest segment in the cancer diagnostics market owing to its utilization in detection of almost every cancer type. MRI, PET, CT, mammography and ultrasound are the major imaging modalities, of which, CT scan and ultrasound imaging account for more than two-third of the total cancer imaging market. A tumor biomarker test is a segment in the cancer diagnostics market with highest research activity. Cancer biomarkers are increasingly being applied in cancer diagnostics; a highly sensitive and specific biomarker essentially helps in better diagnosis, monitoring and prognosis of cancer. Protein-based biomarkers such as alpha-fetoprotein (AFP), cancer embryonic antigen (CEA), prostate-specific antigen (PSA) are among the prominently used tumor biomarkers.

The market for cancer diagnostics is majorly driven by demand from the patients affected with cancers of lung, breast, and colorectal cancer. Lung cancer is the most common cancer of all types and approximately 1.8 billion new cases of lung cancer were diagnosed in 2012. The increasing use of tobacco products in developing nations, particularly in BRICS countries, is contributing to the growing prevalence of lung cancer in the world. In 2013, the global lung cancer diagnostics market accounted for one-fourth of the global cancer diagnostics market revenue. In addition, the rising prevalence of breast cancer among women across the world, particularly in the Asia Pacific, is expected to drive the market for breast cancer diagnostics at the highest CAGR of 8.2% during the forecast period 2014 to 2020.

Read Complete Report @

On the basis of geography, the global cancer diagnostics market is segmented into four major regions, namely, North America, Europe, Asia-Pacific and Rest of the World. In 2013, North America was the largest market for cancer diagnostics followed by Europe. North America is expected to register growth at a CAGR close to 7.0% during the forecast period 2014 to 2020 owing to the rising adoption rate of preventive diagnostic techniques and increasing government initiatives for creating cancer awareness. Moreover, high prevalence and incidence rate of cancer, particularly lung, breast, and prostate cancer, among the population is the driving the growth of the market. In the Asia-Pacific region, developed nations such as Japan and Australia, along with developing nations such as China, India, Singapore, Thailand, etc., are the potential markets that offer enormous opportunities for uptake of cancer diagnostics.

The global cancer diagnostics market is led by players such as Abbott Laboratories, Ambry Genetics, AstraZeneca, bioMerieux, Eli Lilly and Co., Roche, GlaxoSmithKline plc, Novartis, and Pfizer.

Table of Content

1. Introduction

2. Executive Summary

3. Market Overview

4. Global Cancer Diagnostics Market, by Methods

5. Global Cancer Diagnostics Market, by Applications


MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.

Contact US:

Corporate Office

State Tower

90 State Street, Suite 700

Albany, NY 12207

United States

Tel: +1-518-730-0559


%d bloggers like this: